Last reviewed · How we verify

Leucomycin V (Spiramycin I)

unknown active ✓ Verified May 2026

Leucomycin V (generic name: Spiramycin I) is a Spiramycin I drug. It is currently in unknown development.

Spiramycin I works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit.

Leucomycin V is a small molecule with synonyms including Acetylspiromycin, Espiramicina, IL 5902, IL-5902, NSC-55926, and NSC-64393.

At a glance

Generic nameSpiramycin I
Drug classSpiramycin I
Therapeutic areaInfectious Disease
Phaseunknown

Mechanism of action

Imagine your body's cells are like factories that make proteins. Bacteria are like tiny factories that also make proteins, but they can cause harm. Spiramycin I stops these bacterial factories from making proteins by binding to a specific part of the factory, called the 50S ribosomal subunit.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Leucomycin V

What is Leucomycin V?

Leucomycin V (Spiramycin I) is a Spiramycin I drug.

How does Leucomycin V work?

Spiramycin I works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit.

What is the generic name of Leucomycin V?

Spiramycin I is the generic (nonproprietary) name of Leucomycin V.

What drug class is Leucomycin V in?

Leucomycin V belongs to the Spiramycin I class. See all Spiramycin I drugs at /class/spiramycin-i.

What development phase is Leucomycin V in?

Leucomycin V is in unknown.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing